亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer

阿替唑单抗 医学 紫杉醇 肿瘤科 人口 内科学 成本效益 乳腺癌 癌症 彭布罗利珠单抗 免疫疗法 环境卫生 风险分析(工程)
作者
Xiuhua Weng,Xiaoting Huang,Hongchao Li,Lin Shen,Xin Rao,Xianzhong Guo,Pinfang Huang
出处
期刊:American Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (5): 340-348 被引量:29
标识
DOI:10.1097/coc.0000000000000671
摘要

Objective: The authors conducted a cost-effectiveness analysis incorporating recent phase III clinical trial (IMpassion130) data to evaluate the cost-effectiveness of atezolizumab in combination with nab-paclitaxel (AnP) against nab-paclitaxel alone as the first-line treatment for advanced triple-negative breast cancer in developed and developing countries. Materials and Methods: A decision-analytic Markov model was developed using IMpassion130 data to evaluate the cost-effectiveness of AnP over a lifetime from the US health care payer and Chinese health care system perspective. Model inputs were derived from IMpassion130 and published literature. The primary outcomes of the model were quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). Uncertainty was addressed using univariate and probabilistic sensitivity analyses. Results: For the intention-to-treat (ITT) population, the projected mean outcome was better with AnP (1.41 QALYs) than with nab-paclitaxel alone (0.99 QALYs). Similar results were obtained for the programmed death ligand 1 (PD-L1)-positive population, with the obtained mean outcomes of 1.66 and 0.88 QALYs, respectively. For the Unites States, the ICER values comparing AnP with nab-paclitaxel were US$331,996.89 and US$229,359.88 per QALY gained for the ITT and PD-L1-positive populations, respectively. For China, the ICER values were US$106,339.26 and US$72,971.88 per QALY gained for the ITT and PD-L1-positive populations, respectively. The univariate sensitivity analysis indicated that the price of atezolizumab was the most influential factor in our study. AnP had 0% cost-effectiveness at the willingness-to-pay thresholds of US$150,000/QALY in the United States and US$29,383/QALY in China. Conclusion: AnP is not a cost-effective choice as the first-line treatment for advanced triple-negative breast cancer in the United States and China.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
juan完成签到 ,获得积分10
59秒前
学术小垃圾完成签到,获得积分10
1分钟前
叁月二完成签到 ,获得积分10
1分钟前
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
大模型应助科研通管家采纳,获得10
1分钟前
xingsixs完成签到 ,获得积分10
2分钟前
AprilLeung完成签到 ,获得积分10
3分钟前
3分钟前
深情安青应助科研通管家采纳,获得10
3分钟前
迷茫的一代完成签到,获得积分10
4分钟前
魔笛的云宝完成签到 ,获得积分10
4分钟前
www完成签到,获得积分10
5分钟前
5分钟前
NexusExplorer应助科研通管家采纳,获得10
5分钟前
Akitten发布了新的文献求助10
6分钟前
啥时候吃火锅完成签到 ,获得积分0
7分钟前
上官若男应助科研通管家采纳,获得30
7分钟前
斯文败类应助科研通管家采纳,获得10
7分钟前
李爱国应助科研通管家采纳,获得10
7分钟前
科研通AI2S应助科研通管家采纳,获得10
7分钟前
赘婿应助科研通管家采纳,获得10
7分钟前
田様应助精明晓刚采纳,获得10
8分钟前
8分钟前
精明晓刚发布了新的文献求助10
8分钟前
科研通AI2S应助科研通管家采纳,获得10
9分钟前
coolplex完成签到 ,获得积分10
10分钟前
wwe完成签到,获得积分10
10分钟前
貔貅完成签到 ,获得积分10
11分钟前
yindi1991完成签到 ,获得积分10
13分钟前
hgl完成签到,获得积分10
13分钟前
13分钟前
科研通AI2S应助科研通管家采纳,获得10
13分钟前
13分钟前
华仔应助精明晓刚采纳,获得10
14分钟前
14分钟前
14分钟前
精明晓刚发布了新的文献求助10
14分钟前
糖伯虎完成签到 ,获得积分10
15分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990423
求助须知:如何正确求助?哪些是违规求助? 3532158
关于积分的说明 11256513
捐赠科研通 3271046
什么是DOI,文献DOI怎么找? 1805207
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234